Longeveron Inc.

Ladies and gentlemen, greetings and welcome to the Longeviron Third Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star and zero on a telephone keypad. Please be advised that today's conference is being recorded. I would now like to hand the call over to Derek Cole of Investor Relations Advisory Solutions. Please go ahead.

Thank you, Zico. Good afternoon, everyone, and thank you for joining us today to review Longevron's third quarter 2024 financial results and business update. After the U.S. markets closed today, we issued a press release with financial results for the third quarter, which can be found under the investor section of the Longevron website. On the call with me today are Wael Hashad, Chief Executive Officer, Natalia Agafanova, Chief Medical Officer, Lisa Locklear, Chief Financial Officer, and Joshua Hare, Co-Founder, Chief Science Officer, and Chairman of the Board. As a reminder, during this call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from these statements. Any such statement should be considered in conjunction with cautionary statements in our press releases and risk factors discussed in the company's filings. with the Securities and Exchange Commission, which we encourage you to review. Following the company's prepared remarks, we will open the questions from our analysts. With that, let me hand the call over to Wael Hashad, Chief Executive Officer. Wael.

Thank you, Derek. Good afternoon, everyone, and thank you very much for joining us today. We're pleased to update you on our progress and accomplishments since the end of the last quarter. which I can sum it up again as continued strong execution across all aspects of the organization. Today, we also want to talk a little bit about the long-term strategy. As a reminder for those of you newer to our story, Lone Chaperone is a regenerative medicine company developing cutting-edge cellular therapies. Our development compound, Lomacil-B, represents a pipeline and a product opportunity, that is being evaluated across three important treatment areas, addressing numerous unmet medical needs with U.S. market potential opportunity of approximately $10 to $18 billion. Before we get into our recent progress, I would like to ask Dr. Joshua Hare, our co-founder and chief science officer, to discuss an important milestone for large agronomy.